Therapeutic Efficacy of Antiglioma Mesenchymal Extracellular Matrix 131I-Radiolabeled Murine Monoclonal Antibody in a Human Glioma Xenograft Model

Published

Journal Article

The development of Mabs, particularly those reactive with primary brain tumors but not with normal brain, provides a potential means of delivering therapeutic agents selectively to human malignant gliomas. Mab 81C6 an IgG2b immunoglobulin, which defines an epitope of the 000 μC i (P = 0.01). The percentage of anhnals with tumor regression progressively increased with increasing doses of isotope. For radiolabeled 45.6, there were 0 of 10 re seen underestimated the dose observed in a directly measured therapeutic trial by 35-52%. In this xenograft model, a radiolabeled antiglioma Mab against the extracelluhir matrix protein temiscin demonstrated therapeutic efficacy. The promising results obtained in this animal model suggest a potential value for this form of therapy against human malignant gliomas. © 1988, American Association for Cancer Research. All rights reserved.

Duke Authors

Cited Authors

  • Lee, YS; Bullard, DE; Zalutsky, MR; Coleman, RE; Wikstrand, CJ; Friedman, HS; Colapinto, EV; Bigner, D

Published Date

  • January 1, 1988

Published In

Volume / Issue

  • 48 / 3

Start / End Page

  • 584 - 588

Electronic International Standard Serial Number (EISSN)

  • 1538-7445

International Standard Serial Number (ISSN)

  • 0008-5472

Citation Source

  • Scopus